Trial · NCT04423718
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 | At baseline and Week 48 | Visual function of the study eye was assessed at a distance of 4 meters using the ETDRS BCVA letter score. BCVA scale range is 0 (worst) to 100 (best). |
| Secondary | Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 60 | At baseline and Week 60 | Visual function of the study eye was assessed at a distance of 4 meters using the ETDRS BCVA letter score. BCVA scale range is 0 (worst) to 100 (best). |
| Secondary | Percentage of Participants With no Intraretinal Fluid (IRF) and no Subretinal Fluid (SRF) in Central Subfield at Week 16 | At Week 16 | |
| Secondary | Percentage of Participants Gaining at Least 15 Letters in BCVA From Baseline at Week 48 | At baseline and Week 48 | |
| Secondary | Percentage of Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Week 48 | At Week 48 | |
| Secondary | Change in Choroidal Neovascularization (CNV) Size From Baseline to Week 48 | At baseline and Week 48 | |
| Secondary | Change in Total Lesion Area From Baseline to Week 48 | At baseline and Week 48 | |
| Secondary | Percentage of Participants With no Intraretinal Fluid (IRF) and no Subretinal Fluid (SRF) in the Center Subfield at Week 48 | At Week 48 | |
| Secondary | Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 48 | At baseline and Week 48 | |
| Secondary | Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Total Score at Week 48 | At baseline and Week 48 | NEI VFQ-25 was a 25-item questionnaire that gave a score on a scale from 0 (worst) to 100 (best = no vision problems) |
| Secondary | Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Week 48 | Up to Week 48 | |
| Secondary | Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response | Up to week 96 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04423718/registered